Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients
-
- SAGARA Yasuaki
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- KOSHA Shoichiro
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University
-
- BABA Shinichi
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- DOKIYA Fumiko
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- TAMADA Shugo
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- SAGARA Yoshiaki
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- MATSUYAMA Yoshito
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- OHI Yasuyo
- Department of Pathology, Sagara Hospital, Hakuaikai Medical Corporation
-
- ANDO Mitsutake
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- RAI Yoshiaki
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- SAGARA Yoshiatsu
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- DOUCHI Tsutomu
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University
Search this Article
Author(s)
-
- SAGARA Yasuaki
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- KOSHA Shoichiro
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University
-
- BABA Shinichi
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- DOKIYA Fumiko
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- TAMADA Shugo
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- SAGARA Yoshiaki
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- MATSUYAMA Yoshito
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- OHI Yasuyo
- Department of Pathology, Sagara Hospital, Hakuaikai Medical Corporation
-
- ANDO Mitsutake
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- RAI Yoshiaki
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- SAGARA Yoshiatsu
- Department of Breast Oncology, Sagara Hospital, Hakuaikai Medical Corporation
-
- DOUCHI Tsutomu
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kagoshima University
Journal
-
- Breast cancer : the journal of the Japanese Breast Cancer Society
-
Breast cancer : the journal of the Japanese Breast Cancer Society 17(3), 212-217, 2010-07-01
References: 32
-
1
- Effects of third generation aromatase inhibitors on bone health and other safety parameters : results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women
-
MCCLOSKEY EV
Eur J Cancer 43(17), 2523-2531, 2007
Cited by (1)
-
2
- Effect of anastrozole on bone mineral density : 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230
-
EASTELL R
J Clin Oncol. 26(7), 1051-1057, 2008
Cited by (1)
-
3
- Bone health in women with early-stage breast cancer
-
CHLEBOWSKI RT.
Clin Breast Cancer 5(Suppl2), S35-S40, 2005
Cited by (1)
-
4
- Hormone- and chemotherapy-induced bone loss in breast cancer
-
COLEMAN RE.
Oncology (Williston Park) 18(5 Suppl 3), 16-20, 2004
Cited by (1)
-
5
- Predictors of bone mineral loss in patients with ovarian cancer treated with anticancer agents
-
DOUCHI T
Obstet Gynecol. 90(1), 12-15, 1997
Cited by (1)
-
6
- Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients : a phase I study
-
JOHANNESSEN DC
Clin Cancer Res. 3(7), 1101-1108, 1997
Cited by (1)
-
7
- The ATAC (Arimidex, Tamoxifen, alone or in combination) trial : an update
-
BUZDAR AU.
Clin Breast Cancer 5(Suppl 1), S6-S12, 2004
Cited by (1)
-
8
- Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) : a randomised controlled study
-
COLEMAN RE
Lancet Oncol. 8(2), 119-127, 2007
Cited by (1)
-
9
- Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
-
BUZDAR AU
Cancer 112(3 Suppl), 700-709, 2008
Cited by (1)
-
10
- Reducing the risk of bone loss associated with breast cancer treatment
-
HADJI P.
Breast 16(Suppl 3), S10-S15, 2007
Cited by (1)
-
11
- Long-term implications of bone loss in breast cancer
-
AAPRO MS.
Breast 13(Suppl 1), S29-S37, 2004
Cited by (1)
-
12
- Origin of serum estradiol in postmenopausal women
-
JUDD HL
Obstet Gynecol. 59(6), 680-686, 1982
Cited by (1)
-
13
- Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
-
HOWELL A
Lancet 365(9453), 60-62, 2005
Cited by (1)
-
14
- A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
-
THURLIMANN B
N Engl J Med. 353(26), 2747-2757, 2005
Cited by (1)
-
15
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer : 100-month analysis of the ATAC trial
-
FORBES JF
Lancet Oncol. 9(1), 45-53, 2008
Cited by (1)
-
16
- Bone mass and hip axis length in healthy Asian, black, Hispanic, and white American youths
-
WANG MC
J Bone Miner Res. 12(11), 1922-1935, 1997
Cited by (1)
-
17
- The effects of physical exercise on body fat distribution and bone mineral density in postmenopausal women
-
DOUCHI T
Maturitas 35(1), 25-30, 2000
Cited by (1)
-
18
- Safety of aromatase inhibitors in the adjuvant setting
-
PEREZ EA.
Breast Cancer Res Treat. 105(Suppl 1), 75-89, 2007
Cited by (1)
-
19
- A prospective study of body mass index, weight change, and risk of stroke in women
-
REXRODE KM
JAMA 277(19), 1539-1545, 1997
Cited by (1)
-
20
- Effect of an aromatase inhibitor on bond and bone turnover markers : 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)
-
EASTELL R
J Bone Miner Res. 21(8), 1215-1223, 2006
Cited by (1)
-
21
- Letrozole : in postmenopausal hormone-responsive early-stage breast cancer
-
SCOTT LJ
Drugs 66(3), 353-362, 2006
Cited by (1)
-
22
- Evaluating bone mass and bone quality in patients with breast cancer
-
PATERSON AH.
Clin Breast Cancer 5(Suppl 2), S41-S45, 2005
DOI Cited by (2)
-
23
- Strategies to prevent chemotherapy-induced bone loss in women with breast cancer
-
THERIAULT RL.
Clin Breast Cancer 5(Suppl 2), S63-S70, 2005
DOI Cited by (2)
-
24
- Effect of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarker, and plasma lipids in patients with surgically resected early breast cancer
-
LONNING PE
J Clin Oncol 23, 5126-5137, 2005
DOI Cited by (2)
-
25
- Antiaromatase agents : Preclinical data and neoadjuvant therapy
-
MILLER WR
Clin Breast Cancer 1(Suppl), S9-S14, 2000
DOI Cited by (5)
-
26
- <no title>
-
THE ATAC (ARIMIDEX Tamoxifen Alone or in Combination) Trialists' Group
Cancer 98, 1802, 2003
DOI Cited by (3)
-
27
- Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy : A Z-FAST update
-
BRUFSKY A.
Semin Oncol 33(2 Suppl 7), 13-17, 2006
DOI Cited by (2)
-
28
- Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients
-
YONEHARA Yukie , IWAMOTO Ichiro , KOSHA Shoichiro , RAI Yoshiaki , SAGARA Yoshiatsu , DOUCHI Tsutomu
J Obstet Gynaecol Res. 33(5), 696-699, 2007-10-01
Ichushi Web References (26) Cited by (1)
-
30
- Optimizing bisphosphonate therapy in patients with breast cancer endocrine therapy
-
HARVEY HA.
Semin Oncol 31, 23-30, 2004
DOI Cited by (2)
-
31
- Osteoporosis and fracture risk in women of different ethnic groups
-
BARRETT-CONNOR E
J Bone Miner Res 20, 185-194, 2005
DOI Cited by (3)
-
32
- American Society of CIinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer
-
HILLNER B
J CIin Oncol 21, 4042-4057, 2003
DOI Cited by (14)